The Hydrus Microstent in Pseudophakic Patients With Medically Refractory Open-angle Glaucoma.

PURPOSE

Minimally invasive glaucoma surgery (MIGS) is an emerging therapy for glaucoma. The Hydrus Microstent is a MIGS device that stents Schlemm's canal, thereby increasing aqueous drainage and lowering intraocular pressure (IOP). This article describes the use of the microstent in pseudophakic patients with medically refractory glaucoma, a patient population undocumented in the current literature.

PATIENTS AND METHODS

We present a retrospective case series of 11 pseudophakic eyes using 3 or more pressure lowering medications daily for open-angle glaucoma who underwent Hydrus Microstent insertion. Patients were followed up at 1, 3, 6, 12, 24, 36, 48, and 60 months postoperatively and assessed for reductions in IOP and medication burden.

RESULTS

At intervals 12 and 24 months, medication burden reduced by 75.6% at both junctures, and IOP reduced by 43.8% and 34.1%. Complications included 4 hyphaemas and 1 corneal epithelial defect, each of which resolved.

DISCUSSION

This case series demonstrated effective pressure and medication reduction in medically refractory open-angle glaucoma patients using the Hydrus Microstent. Use of this device in this population is thus far undocumented in the literature and may represent an optimal therapeutic modality in the future.